|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.78 USD | +0.59% |
|
-1.64% | +7.63% |
| 07-10 | GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial | AN |
| 07-10 | GSK, Hansoh's targeted cancer drug hits main survival goal in China trial | RE |
| Market Cap | 78.16B 105B 91.73B 84.65B 148B 9,988B 151B 1,012B 397B 4,921B 393B 385B 16,936B | P/E 2026 * |
12.4x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 93.45B 125B 110B 101B 177B 11,941B 180B 1,209B 474B 5,884B 470B 460B 20,249B | EV / Sales 2026 * |
2.76x | EV / Sales 2027 * | 2.54x |
| Free-Float |
92.29% | Yield 2026 * |
3.55% | Yield 2027 * | 3.74% |
Last Transcript: GSK plc
| 1 day | +0.59% | ||
| 1 week | -1.64% | ||
| Current month | +0.69% | ||
| 1 month | +3.15% | ||
| 3 months | -9.33% | ||
| 6 months | +4.74% | ||
| Current year | +7.63% |
| 1 week | 52.3 |  | 54.29 |
| 1 month | 50.43 | | 54.29 |
| Current year | 47.62 | | 61.7 |
| 1 year | 35.45 | | 61.7 |
| 3 years | 31.72 | | 61.7 |
| 5 years | 28.46 | | 61.7 |
| 10 years | 28.46 | | 61.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 31/12/2025 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 30/04/2023 |
| Chief Tech/Sci/R&D Officer | - | 30/11/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 05/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 31/12/2017 |
Jonathan Symonds
CHM | Chairman | 68 | 31/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.59% | -1.64% | - | - | 105B | |
| -2.33% | -2.09% | +50.33% | +162.29% | 1,060B | |
| -0.82% | -2.30% | +62.97% | +61.11% | 619B | |
| -0.73% | -4.98% | +27.22% | +84.46% | 438B | |
| +0.33% | -1.17% | +27.98% | +26.90% | 333B | |
| -0.02% | -2.85% | +25.27% | +44.88% | 282B | |
| -3.89% | -11.22% | +20.78% | +26.07% | 267B | |
| +0.66% | -1.42% | -29.26% | -39.30% | 218B | |
| -0.06% | -2.88% | +20.98% | +61.70% | 196B | |
| -3.72% | -1.10% | +13.35% | +71.53% | 161B | |
| Average | -1.00% | -3.25% | +24.40% | +55.51% | 397.1B | |
| Weighted average by Cap. | -1.26% | -2.96% | +35.28% | +81.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.88B 45.39B 39.76B 36.7B 64.26B 4,330B 65.3B 439B 172B 2,133B 170B 167B 7,342B | 35.61B 47.71B 41.79B 38.57B 67.54B 4,551B 68.64B 461B 181B 2,242B 179B 175B 7,716B |
| Net income | 6.52B 8.74B 7.66B 7.06B 12.37B 834B 12.57B 84.42B 33.1B 411B 32.79B 32.1B 1,413B | 7.04B 9.44B 8.27B 7.63B 13.36B 900B 13.58B 91.17B 35.74B 444B 35.41B 34.66B 1,526B |
| Net Debt | 15.29B 20.48B 17.94B 16.56B 28.99B 1,953B 29.46B 198B 77.56B 962B 76.84B 75.22B 3,312B | 12.22B 16.38B 14.35B 13.24B 23.18B 1,562B 23.56B 158B 62.02B 770B 61.44B 60.15B 2,649B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/07/26 | US$52.78 | +0.59% | 2,867,670 |
| 09/07/26 | US$52.47 | -0.10% | 2,358,079 |
| 08/07/26 | US$52.52 | -1.50% | 3,083,707 |
| 07/07/26 | US$53.32 | +0.43% | 3,673,256 |
| 06/07/26 | US$53.09 | -1.06% | 3,776,825 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
